What You Should Know:
– Recuro Health (Recuro), an integrated digital health solution that evolves healthcare from a reactive, disease-focused model to a personalized, proactive system, today announced the acquisition of MyLegacy, a risk stratification tool and clinical decision support application which uses proprietary algorithms based on practice guidelines developed by the Cleveland Clinic Genomic Medicine Institute.
– The acquisition will further increase the scope and capabilities of Recuro’s digital health platform, pairing automated genetic data gathering with complex care planning to save time, make care more precise and streamline the full continuum of care. Financial details of the acquisition were not disclosed.
– Building comprehensive individual genetic and familial profiles on individuals is typically a very manual process. Normally, genetic assessment is laser-focused on a single disease area, like cancer or in the new area of cardiogenomics, and critical information is commonly missing across the patient’s multiple disease conditions.
